AMP-activated protein kinase and hypoxic pulmonary vasoconstriction. by Robertson, T. P. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMP-activated protein kinase and hypoxic pulmonary
vasoconstriction.
Citation for published version:
Robertson, TP, Mustard, KJ, Lewis, TH, Clark, JH, Wyatt, CN, Blanco, EA, Peers, C, Hardie, DG & Evans,
AM 2008, 'AMP-activated protein kinase and hypoxic pulmonary vasoconstriction.' European Journal of
Pharmacology, vol. 595, no. 1-3, pp. 39-43. DOI: 10.1016/j.ejphar.2008.07.035
Digital Object Identifier (DOI):
10.1016/j.ejphar.2008.07.035
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
European Journal of Pharmacology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
AMP-activated protein kinase and hypoxic pulmonary
vasoconstriction
Tom P. Robertsona, Kirsteen J.W. Mustardc, Tristan H. Lewisa, Jill H. Clarkb, Christopher N.
Wyattd, Elisa A. Blancob, Chris Peersd, D. Grahame Hardiec, and A. Mark Evansb,*
aDepartment of Physiology and Pharmacology, Institute of Comparative Medicine, the University
of Georgia, Athens GA 30602-7389
bMembrane Biology Group, Centre for Integrtive Physiology, School of Biomedical Sciences,
University of Edinburgh, Hugh, Robson Building, George Square, Edinburgh, Scotland UK, EH8
9XD.
cDivision of Molecular Physiology, School of Life Sciences, Wellcome Trust Biocentre, University
of Dundee, Dow Street, Dundee, DD1 5EH, UK.
dDepartment of Neuroscience, Wright State University, 3640 Colonel Glenn Highway, Dayton,
Ohio 45435, USA
eSchool of Medicine, University of Leeds, Leeds, LS2 9JT.
Abstract
Hypoxic pulmonary vasoconstriction is a vital homeostatic mechanism that aids ventilation-
perfusion matching in the lung, for which the underlying mechanism(s) remains controversial.
However, our most recent investigations strongly suggest that hypoxic pulmonary vasoconstriction
is precipitated, at least in part, by the inhibition of mitochondrial oxidative phosphorylation by
hypoxia, an increase in the AMP / ATP ratio and consequent activation of AMP-activated protein
kinase (AMPK). Unfortunately, these studies lacked the definitive proof that can only be provided
by selectively blocking AMPK-dependent signalling cascades. The aim of the present study was,
therefore, to determine the effects of the AMPK inhibitor compound C upon: (1) phosphorylation
in response to hypoxia of a classical AMPK substrate, acetyle CoA carboxylase, in rat pulmonary
arterial smooth muscle and (2) hypoxic pulmonary vasoconstriction in rat isolated intrapulmonary
arteries. Acetyl CoA carboxylase phosphorylation was increased approximately 3 fold in the
presence of hypoxia (pO2 = 16-21 mm Hg, 1 h) and 5-aminoimidazole-4-carboxamide riboside
(AICAR; 1 mM; 4 h) and in a manner that was significantly attenuated by the AMPK antagonist
compound C (40 μM). Most importantly, pre-incubation of intrapulmonary arteries with
compound C (40 μM) inhibited phase II, but not phase I, of hypoxic pulmonary vasoconstriction.
Likewise, compound C (40 μM) inhibited constriction by AICAR (1 mM). The results of the
present study are consistent with the activation of AMPK being a key event in the initiation of the
contractile response of pulmonary arteries to acute hypoxia.
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1. Introduction
Hypoxic pulmonary vasoconstriction is the critical and distinguishing characteristic of the
arteries within the lung(von Euler and Liljestrand, 1946), and contributes to ventilation-
perfusion matching by diverting blood flow to O2-rich areas of the lung. The precise
mechanism(s) by which hypoxia elicits hypoxic pulmonary vasoconstriction is a contentious
issue, although it is clear that relatively mild hypoxia inhibits mitochondrial oxidative
phosphorylation in pulmonary arterial smooth muscle(Archer et al., 1986; Duchen and
Biscoe, 1992a; b; Leach et al., 2001; Shigemori et al., 1996; Youngson et al., 1993) and over
a range of pO2 that elicits no such response in cells that do not function to monitor O2
supply(Duchen and Biscoe, 1992b). Despite this fact, however, little consideration has been
given to the possibility that hypoxic pulmonary vasoconstriction may be dependent on the
subsequent recruitment of AMP-activated protein kinase (AMPK), a central component of a
highly conserved protein kinase signalling cascade that monitors the AMP / ATP ratio as an
index of metabolic stress(Corton et al., 1995b; Hardie and Hawley, 2001; Marsin et al.,
2000; Sakamoto et al., 2005; Shaw et al., 2005; Winder and Hardie, 1996). AMPK is a
heterotrimer comprising a catalytic α subunit and regulatory β and γ subunits. It is activated
by the binding of AMP to two sites on the γ subunit(Hawley et al., 1995; Scott et al., 2002),
leading to allosteric activation of AMPK, phosphorylation of the α subunit at Thr-172 by an
upstream kinase, for example the tumour suppressor kinase LKB1(Hawley et al., 2003;
Shaw et al., 2004; Shaw et al., 2005; Woods et al., 2003), and the inhibition of AMPK
dephosphorylation. These processes are normally antagonized by high concentrations of
ATP, and thereby provide a triple mechanism of regulation that is exquisitely sensitive to
very small changes in the AMP / ATP ratio(Hardie and Hawley, 2001). It is generally
accepted that AMPK functions to maintain ATP supply in all eukaryotic cells by activating
catabolic processes and by inhibiting non-essential ATP consuming processes. However,
AMPK is a serine threonine kinase and may regulate processes outside of
metabolism(Hardie, 2005). Our most recent investigations suggest that inhibition of
mitochondrial oxidative phosphorylation by hypoxia does indeed increase the AMP / ATP
ratio in pulmonary arterial smooth muscle, leading to consequent activation of AMPK and,
in turn, hypoxic pulmonary vasoconstriction (Evans, 2006; Evans et al., 2006a; Evans et al.,
2006b; Evans et al., 2005). However, while these studies provided strong correlations
between the effects of AMPK activation on pulmonary artery function and hypoxic
pulmonary vasoconstriction, they fell short of demonstrating a causal role for AMPK in the
latter process. Here, therefore, we have investigated the effects of the AMPK antagonist
compound C on hypoxic pulmonary vasocontriction.
2. Materials and Methods
2.1 Pulmonary artery isolation and small vessel myography
This investigation conforms to with the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996)
and all protocols were approved by the University of Georgia Institutional Animal Care and
Use Committee. Male Sprague-Dawley rats (250-350g) were killed by decapitation and the
heart and lungs rapidly excised and placed in a cold physiological salt solution (PSS)
containing (in mM): 118 NaCl, 4 KCl, 1 MgSO4, 0.435 NaH2PO4, 24 NaHCO3, 1.8 CaCl2,
5 Na-pyruvate, 5.6 glucose, pH 7.4, 37°C. Small 3rd and 4th order branches of the
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pulmonary arterial tree (200-500 μm internal diameter, i.d.) were dissected free of
connective tissue and mounted in a small vessel myograph (Model 500A, Danish Myo
Technology, Denmark) as previously described in detail(Robertson et al., 2001) and gassed
with 95% air / 5% CO2. Pulmonary artery rings were then equilibrated with 3 exposures to
80 mM K-PSS (2 min duration, isotonic replacement of Na+ by K+), as described
previously(Robertson et al., 2001). To facilitate the hypoxic response, pulmonary arteries
were exposed to 1 μM prostaglandin F2α (PGF2α) for 30 min prior to, and during, the
hypoxic challenge as previously described(Robertson et al., 2000). Hypoxia (16-21 mmHg)
was then induced by gassing with 1% O2 / 95% N2 / 5% CO2 for 45 min, after which time
the vessels were reoxygenated for 20 min, washed with PSS and subsequently re-exposed to
KPSS. Compound C (10-40 μM, a gift from Merck Research Laboratories, Rahway, NJ)
was added to the bathing solution 15 min. prior to the induction of hypoxia. Time-matched
controls were employed in all experimental protocols. The concentrations of compound C
used was selected based upon previous reports where compound C had been found to inhibit
AMPK(Lee et al., 2003; Zhou et al., 2001). Likewise, the effect of compound C (40 μM) on
constriction induced in response to (1) AMPK activation by 5-aminoimidazole-4-
carboxamide riboside (AICAR; 1 mM) and (2) activation of the sarcoplasmic reticulum
store-refilling current by the sarco/endoplasmic reticulum Ca2+ ATPase inhibitor
thapsigargin (1 μM; without and then with extracellular Ca2+; (Mathes and Thompson,
1995)).
2.2 Acetyl CoA carboxylase Phosphorylation
All experiments were performed in accordance with the United Kingdon Animals (Scientific
Procedures) Act 1986. For each sample 32 pulmonary arteries (2nd and 3rd order branches
combined) were excised from 8 animals and carefully threaded onto silk surgical thread.
They were then placed into an enclosed experimental chamber which was filled with PSS-B:
118 NaCl, 4 KCl, 1 MgSO4, 1.2 NaH2PO4, 24 NaHCO3, 2 CaCl2, 2 MgCl2, 5.6 glucose, pH
7.4, 37°C, and bubbled with 75% N2, 20% O2, 5% CO2 (normoxia:150-160 mm Hg) or 93%
N2, 2% O2, 5% CO2 (hypoxia:16-21 mm Hg). Artery samples were exposed, in the absence
and presence of compound C (40 mM), to either: (1) 2 h of normoxia (2)1h of normoxia +
1h of hypoxia or (3) 1h of normoxia and 4h in the presence of AICAR (1mM). Tissue
samples were then quickly removed from the chamber, placed in 1ml centrifuge tubes and
snap frozen in liquid nitrogen. Acetyl CoA carboxylase (ACC) phosphorylation and total
ACC protein levels were analysed using pre-cast 3-8% Tris-acetate gels in Tris-acetate
buffer. ACC phosphorylation and total ACC protein was measured via dual labelling using
phospho-specific antibodies against Ser-221 on ACC2, with secondary anti-sheep antibodies
conjugated to IR680 (1 mg ml-1), and streptavidin conjugated to IR800. Fluorescence from
the two dyes was measured simultaneously using an Odyssey Infrared Imaging System (Li-
Cor Biosciences)(Scott et al., 2002). All tissue samples were assayed in parallel.
2.3 Data presentation and statistical analysis
Contractile responses were calculated as a percentage of the maximal contractile response to
KPSS (% TK) for each vessel. Data for small vessel myography are presented as mean ±
S.E.M., whilst those for ACC phosphorylation represent the mean ± S.D.. Data were
analyzed by repeated measures analysis of variance (ANOVA). Differences between
individual means were determined by Student's modified t-test using the Bonferroni
correction for multiple comparisons between means using the error mean square term from
the ANOVA. A value of P < 0.05 was deemed to be significant.
2.4 Drugs and Chemicals
5-aminoimidazole-4-carboxamide riboside (AICAR) and compound C were obtained from
Molecular Probes. All other drugs and chemicals were obtained from Sigma.
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3. Results
3.1 Compound C inhibits ACC phosphorylation in response to hypoxia and AICAR in
isolated pulmonary arteries
We first assessed the ability of compound C to inhibit ACC phosphorylation in response to
hypoxia and to AMPK activation by AICAR, which is taken up into cells via the adenosine
transporter and metabolised to form the AMP mimetic ZMP(Corton et al., 1995a; Owen et
al., 2000), in pulmonary arterial smooth muscle. Under normoxia (150-160 mmHg) the ratio
of phosphorylated ACC / ACC (pACC/ACC) in 2nd and 3rd order branches of the pulmonary
arterial tree, without endothelium, measured 1.00 ± 0.04 in the absence and 0.58 ± 0.10
(mean ± S.D., P < 0.05, n = 3) in the presence of 40 μM compound C. Upon exposure to
AICAR (1mM) the pACC/ACC ratio rose to 4.23 ± 0.85 and in a manner that was reversed
to 1.49 ± 0.47 (P < 0.05; n = 3) in the presence of 40 μM compound C. Likewise, hypoxia
(16-21 mmHg) increased the pACC/ACC ratio to 4.12 ± 1.03 in the absence and 2.82 ± 0.63
(P < 0.05; n = 3) in the presence of 40 μM compound C. Thus, compound C reduced the
resting pACC/ACC ratio and inhibited the increase thereof in response to hypoxia and
AMPK activation by AICAR (Fig. 1). These data suggest that compound C is an effective
antagonist of AMPK in intact pulmonary arteries.
3.2 Compound C inhibits hypoxic pulmonary vasoconstriction and pulmonary artery
constriction in response to AICAR
Consistent with previous reports, in pulmonary artery rings from 3rd and 4th order branches
of the pulmonary arterial tree, pre-constricted with 1μM PGF2α, acute hypoxic pulmonary
vasoconstriction was biphasic in nature. An initial transient constriction (phase I) peaked at
70.4 ± 2.4% of the constriction to 80 mM K+ (%TK; mean ± S.E.M., n = 10) and within 5
min. of the onset of hypoxia. This was super-imposed on a slowly developing, sustained
constriction (phase II) that peaked at 28.4 ± 2.4%TK (n = 10) after 40 min of hypoxia. Upon
returning to normoxia the vessels rapidly dilated to basal levels of tension (Fig. 2A). When
pulmonary artery rings were pre-incubated with compound C (40μM, 15 min; Fig. 2B)
phase I of hypoxic pulmonary vasoconstriction remained unaffected, measuring 64.82 ±
1.51% %TK (n = 5). In marked contrast, the magnitude of phase II of hypoxic pulmonary
vasoconstriction was markedly reduced to 11.6 ± 1.4 %TK (P < 0.05; n = 5). Fig. 2C shows
the mean response to hypoxia for all time points except that immediately following the peak
of phase I. In Fig. 2D an exemplar record shows the concentration-dependent inhibition of
the sustained phase II of hypoxic pulmonary vasoconstriction by compound C (10-30 μM; n
= 5).
Consistent with its effects on hypoxic pulmonary vasoconstriction, compound C inhibited
pulmonary artery constriction in response to AMPK activation with AICAR. Thus, in the
presence of 1μM PGF2α, exposure of 3rd and 4th order intrapulmonary arteries to AICAR
(1mM) resulted in sustained constriction over a 40 minute period (Fig. 3A). Pre-incubation
of pulmonary arteries with compound C (40μM) significantly inhibited the constriction in
response to AICAR (Fig. 3B), which measured 14.6 ± 1.4% TK (n = 5) and 3.2 ± 2.3 % TK
(n = 6) in the absence and presence of compound C, respectively (P < 0.05).
3.2 Compound C has no effect on basal tone, and is without effect on pulmonary artery
constriction in response to either K-induced depolalrisation, PGF2α or activation of the
store-refilling current
Despite the fact that the basal level of ACC phosphorylation in pulmonary arterial smooth
muscle was inhibited by compound C, basal tone remained unaffected in the presence of
compound C; measuring 13.8 ± 0.8 %TK in its absence and 15.2 ± 1.4%TK in the presence
of 40μM compound C (n = 5).
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In marked contrast to its effects on hypoxic pulmonary vasoconstriction and constriction in
response to AICAR, compound C (40μM) had no discernable effect on pulmonary artery
constriction in response to 80mM K+ (i.e. depolarisation and voltage-gated Ca2+ influx),
which measured 100 ± 1.0%TK and 94.4 ± 3.8%TK, respectively (n = 5; Fig. 3AB), or
constriction in response to PGF2α, which measured 14.7 ± 1.1% TK and 13.3 ± 2.1% TK in
the absence and presence of compound C (40μM; n = 5), respectively. Furthermore, the
constriction in response to Ca2+ entry via the store-refilling current following depletion of
smooth muscle SR stores with thapsigargin (3 μM) remained unaffected in the presence of
compound C (40μM), measuring 44.25 ± 3.1% TK in its absence and 47.43 ± 6.1% TK its
presence (Fig. 4). Note, to deplete SR stores thapsigargin was applied in Ca2+ free solution
(+ 1mM EGTA; equimolar substitution with Mg2+) and the constriction measured upon
subsequent readmission of Ca2+. We may conclude, therefore, that compound C selectively
inhibits hypoxic pulmonary vasoconstriction and pulmonary artery constriction in response
to AMPK activation by AICAR.
4. Discussion
We have recently shown that physiological levels of hypoxia increase the AMP / ATP ratio
in pulmonary artery smooth muscle with concomitant activation of AMPK, and that AMPK
activation by AICAR mimics the characteristics of hypoxic pulmonary
vasoconstriction(Evans et al., 2006a; Evans et al., 2005). As mentioned previously,
however, these studies lacked the definitive evidence that can only be supplied by studying
the impact on hypoxic pulmonary vasoconstriction of blocking AMPK-dependent signalling
pathways.
In the present investigation we therefore sought to provide such evidence by determining the
effects of the AMPK inhibitor, compound C, upon the responses of rat intrapulmonary
arteries to acute hypoxia. Consistent with it acting as an effective AMPK inhibitor in intact
pulmonary arteries, compound C reduced basal levels of phosphorylated acetyl CoA
carboxylase (ACC), a classical AMPK substrate, in pulmonary arterial smooth muscle and
partially reversed ACC phosphorylation induced by both hypoxia and AMPK activation in
response to AICAR.
Most significantly, however, pre-incubation of isolated pulmonary artery rings with
compound C reduced phase II, but not phase I, of hypoxic pulmonary vasoconstriction. In
marked contrast, compound C was without effect on constriction in response to the
vasoconstrictor PGF2α, applied at concentrations which induce pulmonary arterial smooth
muscle constriction by mobilising ryanodine-sensitive SR stores via a mechanism distinct
from that activated by hypoxia(Dipp and Evans, 2001; Dipp et al., 2001). Furthermore,
compound C was ineffective against constriction in response to 80 mM K+ or Ca2+ influx
upon activation of the store-refilling current following SR store depletion with thapsigargin.
The specificity of the AMPK inhibitor compound C is not yet well characterized, but
AICAR is not known to activate any other protein kinases. Thus, the finding that compound
C occludes / reverses hypoxic pulmonary vasoconstriction and constriction by AICAR, but
not constriction in response to voltage-gated Ca2+ influx, PGF2α or Ca2+ influx via the
store-refilling current, provides strong support for the view that the effects observed in our
study are mediated by inhibition of the AMPK pathway. Our results therefore provide
further support for the view that activation of AMPK is necessary as well as sufficient for
hypoxic pulmonary vasoconstriction. However, it should be noted that others have suggested
that compound C may inhibit HIF activation by mechanisms independent of AMPK
(Emerling et al., 2007).
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Fig. 1. Phosphorylation of acetyl CoA carboxylase in response to hypoxia and AICAR is
inhibited by the AMPK antagonist compound C
Bar chart shows the phosphorylated acetyl CoA carboxylase / acetyl CoA carboxylase
(PACC / ACC) ratio measured in pulmonary artery smooth muscle lysates under control
conditions (2h normoxia, 150-160 mm Hg), hypoxia (1h at 16-21 mmHg; following 1h
normoxia) and in the presence of 1 mM AICAR (4h) with and without 40 μM compound C.
Robertson et al. Page 8
Eur J Pharmacol. Author manuscript; available in PMC 2011 June 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 2. Hypoxic pulmonary vasoconstriction is concentration-dependently reversed, and
inhibited, by Compound C
Panel A shows a typical response of a rat IPA to acute hypoxia that was biphasic in nature,
consisting of a transient phase I constriction, superimposed on a sustained phase II
contractile response. Panel B shows a representative response of a time-matched IPA
following pre-incubation (10 min) with compound C (40 μM). Panel C shows the mean
effects of pre-incubation with compound C (40 μM) upon subsequent hypoxic responses in
rat IPA (P<0.05 for 40 μM compound C versus control for all time-points except that
immediately following the peak of phase I). Panel D shows the concentration-dependent
inhibition of the sustained phase II constriction by compound C (10-30 μM)
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Fig. 3. AICAR-induced pulmonary vasoconstriction is inhibited by Compound C
Panel A shows a typical response of a rat IPA to 1 mM AICAR, which consisted of a
slowly-developing sustained constriction. Panel B shows the effects of pre-incubation with
compound C (40 μM) upon the response to 1 mM AICAR in paired IPA.
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Fig. 4. Thapsigargin-induced pulmonary vasoconstriction is not inhibited by Compound C
Typical response of a rat IPA, without endothelium, to 1 μM thapsigargin in the absence (+
1 mM EGTA) and then presence of extracellular Ca2+ and the effect of subsequent
application of compound C (40 μM) to the bathing solution.
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